n°163

September 2015

Issue Contents
Editorial

Free  Oral contraceptives: a good scare

p.200
Third- and fourth-generation oral contraceptives in the hot seat

Marketing Authorisations

Bevacizumab (Avastin°) and age-related macular degeneration

p.201-205
Lower cost does not justify taking risks

Ranibizumab: reject such high (exorbitant) prices

p.205
Editors’ opinion

Apixaban (Eliquis°) in deep vein thrombosis and pulmonary embolism

p.206
Warfarin remains the standard therapy

Free  Aflibercept (Eylea°) and diabetic macular oedema

p.207
A first-choice VEGF inhibitor in case of marked visual loss

Eltrombopag (Revolade°) and thrombocytopenia in patients with hepatitis C

p.208-209
Hepatotoxic drug; more harms than benefits

INN common stem: -olol

p.209

Adverse Effects

Drug-induced lesions of the oesophageal mucosa

p.210-213

Lesions of the oesophageal mucosa and their causes

p.212

Baclofen and pregnancy: birth defects and withdrawal symptoms

p.214
Decision to continue or stop treatment should be made on a case-by-case basis

Reviews

Parkinson's disease: initial treatment of motor disorders

p.215-217
Levodopa and ropinirole

Prevention of deep vein thrombosis

p.217-219
First choice treatments

Breast cancer and duration of tamoxifen

p.220
Harm-benefit balance changes over time

Type 2 diabetes: Mediterranean diet delays need for drug therapy

p.221
Health benefits, no adverse effects

Ischaemic stroke: decide rapidly

p.221
A meta-analysis of individual patient data

Outlook

Stop DSM!

p.222-223
Political issues and the reality of care

Discounted drug prices for hospitals: result in prescriptions for expensive drugs in the community

p.223
A study of nine drug classes

Masthead

Free  Masthead

p.198

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe